文献速递胸部肿瘤乳腺癌消化系统肿瘤

提供有意义的癌症治疗:基于ASCO和ESMO框架评估成本与获益的回顾性队列研究

Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
PubMed 文献 · Lancet Oncol · 2017-06-02

该研究纳入2011年1月1日至2015年12月31日发表的非小细胞肺癌、乳腺癌、结直肠癌和胰腺癌的系统治疗随机对照试验,用ASCO和ESMO框架评估获益,并分析其与药物成本的关系。结果显示两框架一致性仅为一般(κ=0.326),ASCO获益评分与每月增量药物成本呈负相关(ρ=-0.207;p=0.039)。

要点

  • ASCO与ESMO框架对试验获益的判定一致性为一般(κ=0.326)。
  • ASCO获益评分与每月增量药物成本呈负相关(ρ=-0.207;p=0.039)。
  • 达到ESMO获益阈值的治疗中位增量药物成本更低(2981美元 vs 8621美元;p=0.018)。

核心结论

  • ASCO与ESMO两个主要价值医疗框架之间仅存在一般相关性,且框架输出与药物成本呈负相关。
  • 在可持续的医疗系统中提供最佳癌症治疗,将需要未来的肿瘤学家、研究人员和政策制定者协调药物成本与临床获益之间的脱节。

研究设计与样本

  • 回顾性队列研究,纳入2011年1月1日至2015年12月31日发表的非小细胞肺癌、乳腺癌、结直肠癌和胰腺癌的系统治疗随机对照试验,共109项符合条件。
  • 纳入标准为报告了有利于实验组的预设主要或次要结局的显著差异(仅在主要结局不显著时评估次要结局)。
  • 由评估者在相隔3个月的两个时间点使用ASCO和ESMO框架评估试验终点以确认评估者内信度。
  • 计算Cohen's κ统计量以确定两个框架之间基于ASCO评分中位数(作为任意获益阈值)和ESMO框架推荐阈值的一致性。
  • 每月药物成本差异(即增量药物成本)取自2016年平均批发价格。

主要发现

  • 109项随机对照试验中,42项(39%)为非小细胞肺癌,36项(33%)为乳腺癌,25项(23%)为结直肠癌,6项(6%)为胰腺癌。
  • ASCO评分范围为2至77;中位评分为25(IQR 16-35)。
  • 41项(38%)试验达到ESMO框架的获益阈值。
  • 两个框架之间的一致性为一般(κ=0.326)。
  • 在有药物成本数据的100项随机对照试验中,ASCO获益评分与每月增量药物成本呈负相关(ρ=-0.207;p=0.039)。

关键数值与推荐

  • ASCO评分中位数为25(IQR 16-35),作为任意获益阈值用于κ统计量计算。
  • ESMO框架推荐阈值:41项(38%)试验达到该获益阈值。
  • 达到ESMO获益阈值的治疗中位增量药物成本为2981美元(IQR 320-9059),未达到阈值的治疗为8621美元(IQR 1174-13930)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) have developed frameworks that quantify survival gains in light of toxicity and quality of life to assess the benefits of cancer therapies. We applied these frameworks to a cohort of contemporary randomised controlled trials to explore agreement between the two approaches and to assess the relation between treatment benefit and cost. METHODS: We identified all randomised controlled trials of systemic therapies in non-small-cell lung cancer, breast cancer, colorectal cancer, and pancreatic cancer published between Jan 1, 2011, and Dec 31, 2015, and assessed their abstracts and methods. Trials were eligible for inclusion in our cohort if significant differences favouring the experimental group in a prespecified primary or secondary outcome were reported (secondary outcomes were assessed only if primary outcomes were not significant). We assessed trial endpoints with the ASCO and ESMO frameworks at two timepoints 3 months apart to confirm intra-rater reliability. Cohen's κ statistic was calculated to establish agreement between the two frameworks on the basis of the median ASCO score, which was used as an arbitrary threshold of benefit, and the framework-recommended ESMO threshold. Differences in monthly drug cost between the experimental and control groups of each randomised controlled trial (ie, incremental drug cost) were derived from 2016 average wholesale prices. FINDINGS: 109 randomised controlled trials were eligible for inclusion, 42 (39%) in non-small-cell lung cancer, 36 (33%) in breast cancer, 25 (23%) in colorectal cancer, and six (6%) in pancreatic cancer. ASCO scores ranged from 2 to 77; median score was 25 (IQR 16-35). 41 (38%) trials met the benefit thresholds in the ESMO framework. Agreement between the two frameworks was fair (κ=0·326). Among the 100 randomised controlled trials for which drug costing data were available, ASCO benefit score and monthly incremental drug costs were negatively correlated (ρ=-0·207; p=0·039). Treatments that met ESMO benefit thresholds had a lower median incremental drug cost than did those that did not meet benefit thresholds (US$2981 [IQR 320-9059] vs $8621 [1174-13 930]; p=0·018). INTERPRETATION: There is only fair correlation between these two major value care frameworks, and negative correlations between framework outputs and drug costs. Delivery of optimal cancer care in a sustainable health system will necessitate future oncologists, investigators, and policy makers to reconcile the disconnect between drug cost and clinical benefit. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Del Paggio JC, Sullivan R, Schrag D, et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol. 2017. PMID: 28583794. doi:10.1016/S1470-2045(17)30415-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。